{"id":"placebo-human-albumin-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypervolemia"},{"rate":null,"effect":"Pulmonary edema"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Albumin is a naturally occurring plasma protein that increases and maintains oncotic pressure within blood vessels, helping to retain fluid in the intravascular space and prevent fluid shifts into tissues. In clinical use, it is administered intravenously to restore or maintain circulating blood volume in patients with significant fluid loss or hypoproteinemia. As a placebo control in this Phase 3 trial, it provides a physiologically active comparator rather than an inert control.","oneSentence":"Human albumin 1% serves as a volume expander and oncotic agent to maintain intravascular fluid balance and plasma colloid osmotic pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:35.356Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Placebo control in Phase 3 clinical trial (specific indication unknown)"}]},"trialDetails":[{"nctId":"NCT05652504","phase":"PHASE1","title":"Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Malaria","enrollment":400},{"nctId":"NCT04476901","phase":"PHASE2","title":"Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Joshua M Hare","startDate":"2021-05-07","conditions":"Non-ischemic Dilated Cardiomyopathy","enrollment":136},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT05722938","phase":"PHASE3","title":"Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)","status":"RECRUITING","sponsor":"Biotest","startDate":"2023-09-09","conditions":"Community-acquired Pneumonia","enrollment":590},{"nctId":"NCT02922413","phase":"PHASE2","title":"Panhematin for Prevention of Acute Attacks of Porphyria","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2015-10-30","conditions":"Acute Intermittent Porphyria, Hereditary Coproporphyria, Variegate Porphyria","enrollment":13},{"nctId":"NCT07371624","phase":"PHASE1, PHASE2","title":"A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke.","status":"RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2025-12-31","conditions":"Acute Ischemic Stroke","enrollment":54},{"nctId":"NCT03265808","phase":"PHASE1, PHASE2","title":"Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.","status":"COMPLETED","sponsor":"Ihsan M Salloum, MD, MPH","startDate":"2018-03-18","conditions":"Major Depressive Disorder, Alcohol Use Disorder","enrollment":31},{"nctId":"NCT03818854","phase":"PHASE2","title":"Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Michael A. Matthay","startDate":"2019-11-26","conditions":"Respiratory Distress Syndrome, Adult","enrollment":120},{"nctId":"NCT04701034","phase":"PHASE2","title":"Intravenous Immunoglobulin and Prednisolone for RPL After ART.","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2021-01-28","conditions":"Habitual Abortion, Recurrent Pregnancy Loss, Fertility Disorders","enrollment":80},{"nctId":"NCT02346747","phase":"PHASE2","title":"A Trial of Vigil for Participants With Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gradalis, Inc.","startDate":"2015-02","conditions":"Ovarian Cancer, Ovarian Neoplasms","enrollment":92},{"nctId":"NCT04869397","phase":"PHASE2","title":"Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells","status":"TERMINATED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-06-14","conditions":"Covid19","enrollment":19},{"nctId":"NCT06934473","phase":"NA","title":"Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals","status":"RECRUITING","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2025-05-21","conditions":"Bloodpressure","enrollment":16},{"nctId":"NCT05148286","phase":"PHASE4","title":"Albumin and Crystalloid Administration in Septic Shock","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-01-17","conditions":"Septic Shock","enrollment":2426},{"nctId":"NCT05531149","phase":"PHASE3","title":"Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia","status":"TERMINATED","sponsor":"Biotest","startDate":"2022-12-22","conditions":"Respiratory Infection, Pneumonia, Community-acquired Pneumonia","enrollment":107},{"nctId":"NCT04061746","phase":"PHASE1","title":"Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2020-02-27","conditions":"Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT06738576","phase":"PHASE1","title":"Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106), Female Urinary Incontinence Women Over 50 Years Old","status":"RECRUITING","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2024-12-16","conditions":"Urinary Incontinence Stress","enrollment":60},{"nctId":"NCT03520790","phase":"PHASE1","title":"Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-12-05","conditions":"Pancreatic Cancer","enrollment":36},{"nctId":"NCT04466098","phase":"PHASE2","title":"Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2020-07-30","conditions":"Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia","enrollment":8},{"nctId":"NCT06740149","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-03-01","conditions":"Acute-On-Chronic Liver Failure","enrollment":90},{"nctId":"NCT05604521","phase":"PHASE1","title":"A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI","status":"TERMINATED","sponsor":"Sanaria Inc.","startDate":"2022-12-06","conditions":"Malaria, Malaria,Falciparum","enrollment":31},{"nctId":"NCT06146062","phase":"PHASE2","title":"Effects of Intravascular Administration of Mesenchymal Stromal Cells Derived from Wharton's Jelly of the Umbilical Cord on Systemic Immunomodulation and Neuroinflammation After Traumatic Brain Injury.","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-25","conditions":"Traumatic Brain Injury","enrollment":68},{"nctId":"NCT02673931","phase":"NA","title":"GLP-1 and Hyperoxia for Organ Protection in Heart Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2016-02","conditions":"Coronary Disease, Shock, Cardiogenic, Renal Failure","enrollment":1400},{"nctId":"NCT06534450","phase":"PHASE3","title":"The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dobri Kiprov","startDate":"2022-09-12","conditions":"Aging","enrollment":40},{"nctId":"NCT06491043","phase":"PHASE2","title":"Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells","status":"RECRUITING","sponsor":"Meribank Biotech Co., Ltd.","startDate":"2024-06-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":90},{"nctId":"NCT05054803","phase":"PHASE1, PHASE2","title":"Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury","status":"COMPLETED","sponsor":"Banc de Sang i Teixits","startDate":"2021-10-13","conditions":"Spinal Cord Injury Cervical","enrollment":18},{"nctId":"NCT04992832","phase":"PHASE1, PHASE2","title":"Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction（PRIME-HFrEF Study）","status":"COMPLETED","sponsor":"Shanghai East Hospital","startDate":"2021-07-28","conditions":"Heart Failure, Systolic","enrollment":40},{"nctId":"NCT02549170","phase":"PHASE3","title":"A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-12-15","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":138},{"nctId":"NCT02587572","phase":"PHASE2","title":"Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial","status":"WITHDRAWN","sponsor":"Longeveron Inc.","startDate":"2023-12-01","conditions":"Metabolic Disease, Endothelial Dysfunction","enrollment":""},{"nctId":"NCT01376778","phase":"PHASE3","title":"A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)","status":"COMPLETED","sponsor":"The George Washington University Biostatistics Center","startDate":"2012-04","conditions":"Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection","enrollment":399},{"nctId":"NCT04576728","phase":"PHASE2","title":"Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19","status":"COMPLETED","sponsor":"Biotest","startDate":"2020-10-06","conditions":"Covid19","enrollment":166},{"nctId":"NCT04399889","phase":"PHASE1, PHASE2","title":"hCT-MSCs for COVID19 ARDS","status":"TERMINATED","sponsor":"Joanne Kurtzberg, MD","startDate":"2020-06-18","conditions":"COVID, Corona Virus Infection, COVID19","enrollment":12},{"nctId":"NCT05631444","phase":"PHASE1, PHASE2","title":"Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia","status":"COMPLETED","sponsor":"Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle","startDate":"2019-01-01","conditions":"Chronic Limb-threatening Ischemia, Diabetes Mellitus","enrollment":24},{"nctId":"NCT04810429","phase":"PHASE4","title":"Comparison of Temporomandibular Joint Arthroscopy With Botulinum Toxin Injection Versus Placebo","status":"COMPLETED","sponsor":"Instituto Portugues da Face","startDate":"2021-01-01","conditions":"Temporomandibular Joint Disorders","enrollment":15},{"nctId":"NCT04490486","phase":"PHASE1","title":"Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19","status":"WITHDRAWN","sponsor":"Joshua M Hare","startDate":"2022-10-01","conditions":"COVID-19, Acute Respiratory Distress Syndrome, Corona Virus Infection","enrollment":""},{"nctId":"NCT01745783","phase":"PHASE1, PHASE2","title":"Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis","status":"COMPLETED","sponsor":"Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud","startDate":"2013-01","conditions":"Multiple Sclerosis","enrollment":26},{"nctId":"NCT04492475","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 3 (ACTT-3)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-05","conditions":"COVID-19","enrollment":969},{"nctId":"NCT02600130","phase":"PHASE1","title":"Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Longeveron Inc.","startDate":"2016-10-10","conditions":"Alzheimer's Disease","enrollment":33},{"nctId":"NCT05121870","phase":"PHASE2","title":"Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis","status":"UNKNOWN","sponsor":"Beijing 302 Hospital","startDate":"2021-09-01","conditions":"Decompensated Cirrhosis","enrollment":240},{"nctId":"NCT05080543","phase":"PHASE1","title":"Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients","status":"UNKNOWN","sponsor":"Amany Mousa Salama Muhammed","startDate":"2021-10","conditions":"Septic Shock","enrollment":36},{"nctId":"NCT03656198","phase":"PHASE4","title":"Non-specific Effects of Rabies Vaccine","status":"COMPLETED","sponsor":"Ross University School of Veterinary Medicine","startDate":"2018-08-29","conditions":"Influenza-like Illness, Upper Respiratory Disease, Diarrhea","enrollment":546},{"nctId":"NCT02849418","phase":"PHASE3","title":"Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-11","conditions":"Urinary Bladder, Overactive","enrollment":21},{"nctId":"NCT01651351","phase":"PHASE4","title":"GLASSIA Infusion Rate Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2012-07-31","conditions":"Alpha1-antitrypsin Deficiency, Healthy Volunteers","enrollment":30},{"nctId":"NCT00666263","phase":"PHASE3","title":"Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2008-08-22","conditions":"Multifocal Motor Neuropathy","enrollment":50},{"nctId":"NCT02722304","phase":"PHASE3","title":"Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency","status":"TERMINATED","sponsor":"Baxalta now part of Shire","startDate":"2016-11-02","conditions":"Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency","enrollment":7},{"nctId":"NCT02627456","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-09","conditions":"Malaria","enrollment":409},{"nctId":"NCT04243382","phase":"PHASE2","title":"Treatment of Children With Autistic Spectrum Disorder With Autologous Umbilical Cord Blood, a Pilot Study","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2020-02-27","conditions":"Autistic Spectrum Disorder","enrollment":60},{"nctId":"NCT04243408","phase":"PHASE2","title":"Treatment of Children With Cerebral Palsy With Autologous Umbilical Cord Blood, a Pilot Study","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2020-07-08","conditions":"Cerebral Palsy","enrollment":72},{"nctId":"NCT02820844","phase":"PHASE3","title":"Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-10","conditions":"Urinary Bladder, Overactive","enrollment":250},{"nctId":"NCT02503280","phase":"PHASE1, PHASE2","title":"The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.","status":"WITHDRAWN","sponsor":"Joshua M Hare","startDate":"2025-03-01","conditions":"Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction","enrollment":""},{"nctId":"NCT03876197","phase":"PHASE1, PHASE2","title":"Mesenchymal Stem Cells for Radiation-induced Xerostomia","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2020-08-01","conditions":"Radiation Toxicity, Xerostomia Due to Radiotherapy, Dry Mouth","enrollment":30},{"nctId":"NCT03394508","phase":"PHASE2, PHASE3","title":"The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2013-01","conditions":"Rhinitis, Asthma, Allergy","enrollment":30},{"nctId":"NCT04562025","phase":"NA","title":"Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy","status":"UNKNOWN","sponsor":"Renmin Hospital of Wuhan University","startDate":"2020-09-25","conditions":"Diabetic Nephropathy","enrollment":38},{"nctId":"NCT04288102","phase":"PHASE2","title":"Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)","status":"COMPLETED","sponsor":"Beijing 302 Hospital","startDate":"2020-03-05","conditions":"Corona Virus Disease 2019(COVID-19)","enrollment":100},{"nctId":"NCT02715804","phase":"PHASE3","title":"A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma","status":"TERMINATED","sponsor":"Halozyme Therapeutics","startDate":"2016-03-14","conditions":"Pancreatic Ductal Carcinoma","enrollment":492},{"nctId":"NCT03261167","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-08-02","conditions":"Spasticity, Post-Stroke","enrollment":124},{"nctId":"NCT04273646","phase":"NA","title":"Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2020-04-20","conditions":"2019 Novel Coronavirus Pneumonia, COVID-19","enrollment":48},{"nctId":"NCT04293692","phase":"NA","title":"Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus","status":"WITHDRAWN","sponsor":"Puren Hospital Affiliated to Wuhan University of Science and Technology","startDate":"2020-02-24","conditions":"COVID-19","enrollment":""},{"nctId":"NCT02239393","phase":"PHASE2","title":"Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2015-06","conditions":"Multiple Sclerosis","enrollment":31},{"nctId":"NCT04210193","phase":"PHASE2, PHASE3","title":"Is Intralymphatic Allergen Immunotherapy Effective and Safe?","status":"COMPLETED","sponsor":"Lars Olaf Cardell","startDate":"2014-04-25","conditions":"Allergic Rhinitis Due to Grass Pollen","enrollment":15},{"nctId":"NCT01843894","phase":"PHASE1, PHASE2","title":"A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye","status":"COMPLETED","sponsor":"R-Tech Ueno, Ltd.","startDate":"2013-04","conditions":"Dry Eye","enrollment":104},{"nctId":"NCT00587990","phase":"PHASE1, PHASE2","title":"Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)","status":"TERMINATED","sponsor":"Joshua M Hare","startDate":"2007-11","conditions":"Stem Cell Transplantation, Ventricular Dysfunction, Left","enrollment":9},{"nctId":"NCT02971631","phase":"NA","title":"Gastrectomy, Eating Behaviour and GLP-1","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-08-10","conditions":"Gastric Cancer, Dumping Syndrome","enrollment":5},{"nctId":"NCT01769573","phase":"PHASE1","title":"A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2013-07","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT02675556","phase":"PHASE1","title":"Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression","status":"TERMINATED","sponsor":"Joshua M Hare","startDate":"2017-10-31","conditions":"Treatment Resistant Depression","enrollment":1},{"nctId":"NCT01951729","phase":"PHASE1","title":"The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-03-13","conditions":"Pre-diabetes","enrollment":15},{"nctId":"NCT00798915","phase":"PHASE1","title":"Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2008-12","conditions":"Diabetes","enrollment":40},{"nctId":"NCT01951716","phase":"PHASE1","title":"Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2013-01","conditions":"Does the Vagus Nerve Mediate the Effects of Xenin-25","enrollment":""},{"nctId":"NCT02223169","phase":"NA","title":"Human Intervention Study of Egg Protein Derivative on Cardiovascular Risk","status":"COMPLETED","sponsor":"University College Cork","startDate":"2014-04","conditions":"Hypertension","enrollment":69},{"nctId":"NCT01050114","phase":"PHASE3","title":"OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER","status":"UNKNOWN","sponsor":"Christopher Patrick Smith","startDate":"2013-08","conditions":"Overactive Bladder","enrollment":36},{"nctId":"NCT00220779","phase":"PHASE2","title":"Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2002-12","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":128},{"nctId":"NCT02203968","phase":"PHASE1, PHASE2","title":"Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2014-10","conditions":"Trauma, Injury, Bleeding","enrollment":50},{"nctId":"NCT02591849","phase":"NA","title":"GLP-1 Effects on Insulin and Glucagon in PTDM","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2014-10","conditions":"Post-transplant Diabetes Mellitus","enrollment":24},{"nctId":"NCT00220740","phase":"PHASE3","title":"Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-04","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":117},{"nctId":"NCT00220805","phase":"PHASE2","title":"Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-01","conditions":"Macular Degeneration","enrollment":96},{"nctId":"NCT01513135","phase":"PHASE2","title":"A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers","status":"COMPLETED","sponsor":"Barbara Ensoli, MD","startDate":"2012-03","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00768066","phase":"PHASE1, PHASE2","title":"The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)","status":"COMPLETED","sponsor":"University of Miami","startDate":"2008-08","conditions":"Stem Cell Transplantation, Ventricular Dysfunction, Left","enrollment":65},{"nctId":"NCT01887366","phase":"PHASE2","title":"Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-06","conditions":"Cocaine Addiction","enrollment":208},{"nctId":"NCT01420744","phase":"PHASE2","title":"Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP","status":"COMPLETED","sponsor":"Biotest","startDate":"2011-08","conditions":"Community Acquired Pneumonia","enrollment":160},{"nctId":"NCT00684060","phase":"PHASE2","title":"Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2008-07","conditions":"Left Ventricular Dysfunction","enrollment":87},{"nctId":"NCT00684021","phase":"PHASE2","title":"Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2008-07","conditions":"Left Ventricular Dysfunction","enrollment":120},{"nctId":"NCT00990509","phase":"PHASE2","title":"Albumin for Intracerebral Hemorrhage Intervention","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2009-09","conditions":"Intracerebral Hemorrhage","enrollment":14},{"nctId":"NCT00949663","phase":"PHASE1","title":"Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":38},{"nctId":"NCT00024518","phase":"PHASE2","title":"Interferon-Alpha for Diabetes Mellitus Type 1","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2001-09","conditions":"Insulin-Dependent Diabetes Mellitus","enrollment":57},{"nctId":"NCT01867645","phase":"PHASE1","title":"The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2004-12","conditions":"Polyneuropathies","enrollment":38},{"nctId":"NCT00280280","phase":"PHASE1","title":"Botox vs. Baclofen for Upper Limb Spasticity","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2006-02","conditions":"Spasticity","enrollment":8},{"nctId":"NCT00068055","phase":"PHASE1, PHASE2","title":"IVIG - West Nile Encephalitis: Safety and Efficacy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-09","conditions":"West Nile Virus","enrollment":62},{"nctId":"NCT01254123","phase":"PHASE3","title":"Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2009-11","conditions":"Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (human albumin 1%)","genericName":"Placebo (human albumin 1%)","companyName":"Biotest","companyId":"biotest","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Human albumin 1% serves as a volume expander and oncotic agent to maintain intravascular fluid balance and plasma colloid osmotic pressure. Used for Placebo control in Phase 3 clinical trial (specific indication unknown).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}